Literature DB >> 1313876

Development of a series of phenyltetrazole leukotriene D4 (LTD4) receptor antagonists.

R W Harper1, D K Herron, N G Bollinger, J S Sawyer, R F Baldwin, C R Roman, L E Rinkema, J H Fleisch.   

Abstract

A hypothetical model for receptor binding of leukotriene D4 (LTD4) was deduced from conformational analysis of LTD4 and from the structure-activity relationships (SAR) of known LTD4 receptor antagonists. A new structural series of LTD4 receptor antagonists exemplified by 5-[4-(4-phenylbutoxy)phenyl]-2-[4-(tetrazol-5-yl)butyl]-2H-t etrazole was designed in which a phenyltetrazole moiety was incorporated as a receptor binding equivalent of the triene unit of LTD4. A number of these phenyltetrazoles were prepared and found to possess LTD4 receptor antagonist activity. The structure-activity relationship (SAR) of this series is described.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313876     DOI: 10.1021/jm00085a004

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  A proposed common spatial pharmacophore and the corresponding active conformations of some peptide leukotriene receptor antagonists.

Authors:  V Hariprasad; V M Kulkarni
Journal:  J Comput Aided Mol Des       Date:  1996-08       Impact factor: 3.686

2.  Ovulation sources coagulation protease cascade and hepatocyte growth factor to support physiological growth and malignant transformation.

Authors:  Hsuan-Shun Huang; Pao-Chu Chen; Sung-Chao Chu; Ming-Hsun Lee; Chi-Ya Huang; Tang-Yuan Chu
Journal:  Neoplasia       Date:  2021-10-21       Impact factor: 5.715

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.